{"symbol":"ABT","fiscalQuarter":"Q2-2026","reportDate":"2026-07-16","reportTime":"BMO","status":"upcoming","company":{"name":"Abbott Laboratories","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABT/earnings/Q2-2026","estimates":{"consensusEps":1.2772,"consensusRevenue":12536.09,"epsLow":1.26,"epsHigh":1.29,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. With a market cap of $193 billion, Abbott plays a crucial role in the health care sector, focusing on innovation and improving patient outcomes.","keyMetrics":[{"name":"EPS","why":"Earnings per share (EPS) is a key indicator of profitability and will show how well Abbott is managing its costs and revenue.","consensus":"$1.28"},{"name":"Revenue","why":"Total revenue provides insight into the overall sales performance and demand for Abbott's products.","consensus":"$12.5B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Abbott reported an EPS of $1.15, slightly beating estimates. However, the stock dropped 6% the following day, indicating market disappointment despite the earnings beat.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Abbott to report steady earnings and revenue growth this quarter, with a consensus EPS of $1.28 and revenue of $12.5 billion. Investors are closely watching for any signs of growth in key product lines.","bullCase":"If Abbott can exceed EPS expectations and demonstrate strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.","bearCase":"Conversely, if Abbott fails to meet earnings expectations or shows signs of declining sales, it could lead to further stock price declines, especially given the recent performance."},"optionsSignal":{"impliedMove":"8.67%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+0.61%","reaction":"-6.00%"},{"quarter":"Q4-2025","epsSurprise":"+0.20%","reaction":"-10.04%"},{"quarter":"Q3-2025","epsSurprise":"+0.15%","reaction":"-2.87%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"-8.52%"},{"quarter":"Q1-2025","epsSurprise":"+1.96%","reaction":"+2.76%"}],"pivotalQuestions":[{"question":"Will Abbott's EPS exceed the consensus estimate of $1.28?","whyItMatters":"A beat on EPS could indicate strong operational performance and boost investor confidence."},{"question":"What are the revenue figures for Abbott's key product segments?","whyItMatters":"Understanding revenue performance in key areas will help gauge overall business health and future growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.30 or higher would confirm the bull case and suggest strong demand for Abbott's products.","bearTrigger":"An EPS below $1.26 would support the bear case, indicating potential struggles in revenue generation.","context":"This quarter, the focus is on Abbott's ability to maintain profitability and revenue growth amid market challenges."},"scenarioPlaybook":{"beatAndRaise":"If Abbott beats expectations, history suggests the stock could rise by around 4.62% on the first day, confirming positive market sentiment.","inLineCautious":"If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.","miss":"A miss on earnings could lead to a decline in stock price, with historical data indicating an average drop of around 3.34% following such events."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate Abbott's ability to leverage new product launches, which could drive higher-than-expected revenue growth this quarter.","supportingPoints":["Abbott's recent product innovations have not been fully reflected in analyst estimates.","The options market is pricing for a larger move than historical averages suggest, indicating potential surprises.","Recent insider buying suggests confidence in Abbott's future performance."],"riskToConsensus":"If Abbott's new product lines show stronger sales than anticipated, it could significantly alter revenue expectations."},"whatToListenFor":["Updates on sales performance for Abbott's new product launches.","Any commentary on cost management and operational efficiency.","Insights into market demand trends in key segments.","Management's outlook for the remainder of the fiscal year.","Details on any regulatory changes affecting Abbott's product lines."],"metaDescription":"Abbott Laboratories (ABT) reports Q2 2026 earnings July 16. Analysts expect $1.28 EPS on $12.5B revenue. Here's what to watch."}}